| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281351 | Clinical Gastroenterology and Hepatology | 2015 | 26 Pages |
Abstract
Based on base-case values, it is not cost effective to perform a biopsy analysis to detect celiac disease in patients undergoing an EGD for refractory GERD. However, the approach becomes cost effective when the prevalence of celiac disease in this population is 1.8% or greater.
Keywords
CPTEMADGPPPITTGEGDICERGERDGFDQALYtissue transglutaminase antibodiesEndomysial antibodiesCurrent Procedural Terminologyesophagogastroduodenoscopygastroesophageal reflux diseaseCeliac diseaseGluten-free dietQuality-adjusted life-yearScreeningProton pump inhibitorIncremental cost-effectiveness ratioAntibody
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Janie J. Yang, Anusorn Thanataveerat, Peter H.R. Green, Benjamin Lebwohl,